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Dendritic Cells (DC) may influence the development of a
natural immune response and could be potentially effec-
tive in specific treatments for cancer patients. A phase I-II
vaccination trial for patients with advanced melanoma
and renal cell carcinoma (RCC) is ongoing in our Depart-
ment of Oncology. In the present study we compared the
therapeutic use of intradermally administered immature
DC (iDC) and mature DC (mDC) pulsed with autologous
tumor lysate (ATL) and keyhole limpet hemocyanin
(KLH). iDC were differentiated from adherent PBMC
obtained by leukapheresis and cultured with IL-4 (1000
IU/ml) and GM-CSF (1000 IU/ml) for 6 days. ATL and
KLH were added on the 6th day. On the 7th day iDC were
used for therapeutic infusion in 9 patients, while mDC,
obtained after a further 48-hour stimulation with IL-1β,
IL-6, TNFα and PGE2, were administered in 10 successive
patients. Treatment schedule was as follows: vaccination
on days 0 and 16, and once a month thereafter for at least
5 cycles or until progression occurred. Patients received IL-
2 subcutaneously at a dose of 3,000,000 IU/die from days
2 to 6 of each cycle. Of the 9 patients (8 melanoma and 1
RCC) treated with iDC, 4 showed stable disease (SD) of
19, 6, 6, and 6 months' duration, and 5 progressed. Four
of these patients also had weak delayed-type hypersensi-
tivity (DTH) skin reactions for KLH or ATL. The 10
patients (9 melanoma and 1 RCC) treated with mDC
obtained the following results: 1 complete response
(abdominal lymph nodes) of 10+ months' duration, with
positive DTH for both ATL and KLH and onset of vitiligo,
1 partial response (lung and lymph nodes) of 3 months'
duration, with subsequent development of brain metas-
tases, 1 mixed response (skin and lymph nodes) lasting 6
months with positive DTH for both ATL and KLH and
subsequent development of brain metastases, 3 SD of 9
(RCC patient), 9 and 7+ months' duration with positive
DTH only for KLH (one patient progressed with brain
metastases). Four patients with negative DTH for ATL pro-
gressed (1 brain metastases). mDC vaccination appears to
be more effective in inducing clinical and immunological
responses than iDC. In particular, 2 responder patients
showed evidence of an immunological response that was
specific for ATL. The disease would seem to have a high
propensity to spread to the Central Nervous System, and
a form of protection with liposoluble chemotherapy
could therefore be hypothesized in future.
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